TSE:CPH - Cipher Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$2.98 +0.13 (+4.56 %)
(As of 06/24/2018 04:00 PM ET)
Previous CloseC$2.98
Today's RangeC$2.84 - C$2.98
52-Week RangeC$2.65 - C$5.75
Volume27,100 shs
Average Volume38,861 shs
Market CapitalizationC$106 million
P/E RatioN/A
Dividend YieldN/A
Cipher Pharmaceuticals logoCipher Pharmaceuticals Inc., together with its subsidiaries, operates as a specialty pharmaceutical company in Canada. It offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CONZIP/ DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. The company also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101, an oral small molecule drug that is used for the treatment of plaque psoriasis and rheumatoid arthritis; and ASF-1096 for the treatment of anorectal indications. It also develops tattoo removal creams, which is in the pre-clinical stage. The Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and sale of TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.

Receive CPH News and Ratings via Email

Sign-up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins32.44%
Return on Equity75.47%
Return on Assets26.48%


Outstanding Shares26,765,000

The Truth About Cryptocurrencies

Cipher Pharmaceuticals (TSE:CPH) Frequently Asked Questions

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH."

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (TSE:CPH) issued its earnings results on Thursday, May, 10th. The company reported $0.03 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.02 by $0.01. The company had revenue of $5.78 million for the quarter, compared to the consensus estimate of $6 million. Cipher Pharmaceuticals had a net margin of 32.44% and a return on equity of 75.47%. View Cipher Pharmaceuticals' Earnings History.

When is Cipher Pharmaceuticals' next earnings date?

Cipher Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for Cipher Pharmaceuticals.

What price target have analysts set for CPH?

2 brokers have issued 12-month target prices for Cipher Pharmaceuticals' shares. Their predictions range from C$4.25 to C$4.25. On average, they expect Cipher Pharmaceuticals' share price to reach C$4.25 in the next year. View Analyst Ratings for Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen L. Lemieux, CFO & Sec.
  • Mr. Norman Evans, Consultant (Age 63)
  • Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 50)
  • Mr. Chris Watters, VP of Corp. Devel.

Has Cipher Pharmaceuticals been receiving favorable news coverage?

News coverage about CPH stock has been trending somewhat positive this week, according to Accern Sentiment. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cipher Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also gave headlines about the company an impact score of 45.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of CPH stock can currently be purchased for approximately C$2.98.

How big of a company is Cipher Pharmaceuticals?

Cipher Pharmaceuticals has a market capitalization of C$106 million.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.

MarketBeat Community Rating for Cipher Pharmaceuticals (CPH)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  194
MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.